Combination therapy of angiotensin converting enzyme inhibitor and angiotensin AT1 receptor antagonist in diabetic nephropathy

Hong Kong Journal of Nephrology

Volumn 9, Issue 1, 2007, Pages 31-35

  Saito, Tomoyuki ^a   Saito, Takako ^a   Tamemoto, Hiroyuki ^a   Yuzawa, Miho ^a   Sasaki, Masami ^a   Ikoma, Aki ^a   Kawakami, Masanobu ^a   Ishikawa, San E ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Albuminuria; Angiotensin AT1 receptor antagonist; Angiotensin converting enzyme inhibitor; Combination therapy; Diabetic nephropathy

Indexed keywords

CREATININE; IMIDAPRIL; INSULIN; LOSARTAN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIET THERAPY; DRUG DOSE INCREASE; FEMALE; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RATING SCALE;

EID: 34249810392     PISSN: 15615413     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1561-5413(07)60006-4     Document Type: Article

References (25)

1. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
5. Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996;39:1646-54.
6. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35:155-63.
7. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32:488-95.
8. Hostetter TH. Mechanisms of diabetic nephropathy. Am J Kidney Dis 1994;23:188-92.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The Collaborative Study Group. N Engl J Med 2001; 345:851-60.
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
13. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256-61.
14. Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 2002;55:113-21.
15. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99:1926-35.
16. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
17. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM. Combination of ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19:1-6.
18. Sterqiou GS, Skeva II, Baibas NM, Kalkana CB, Roussias LG, Mountokalakis TD. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the anti-hypertensive response to angiotensin receptor antagonism? Am J Hypertens 2001;14:688-93.
19. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazapril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95.
20. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109: 2492-9.
21. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000;77:S93-8.
22. Manley HJ. Role of angiotensin-converting-enzyme inhibition in patients with renal disease. Am J Health Syst Pharm 2000;57: S12-8.
23. Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogiwara T. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005;18:13-7.
24. Song JH, Cha SH, Hong SB, Kim DH. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens 2006;24:S101-6.
25. Matos JPS, de Lourdes Rodrigues M, Ismerim VL, Boasqueviscue EM, Genelhu V, Francischetti EA. Effects of dual blockade of the renin-angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin Nephrol 2005;64:180-9.